Lv4
670 积分 2024-05-07 加入
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
7天前
已完结
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
7天前
已完结
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
7天前
已完结
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
7天前
已关闭
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
7天前
已完结
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class
7天前
已完结
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
7天前
已完结
Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study
7天前
已完结
Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España
7天前
已完结
Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
7天前
已完结
皖公网安备34019202002308
